Early postprandial glucagon surge affects postprandial glucose levels in obese and non-obese patients with type 2 diabetes

Endocrine Journal

Volumn 60, Issue 6, 2013, Pages 813-818

  Kozawa, Junji ^a   Okita, Kohei ^a   Iwahashi, Hiromi ^a   Yamagata, Kazuya ^b   Imagawa, Akihisa ^a   Shimomura, Iichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Glucagon; Incretin; Obesity; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC PATIENT; FEEDING BEHAVIOR; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POPULATION RESEARCH;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; GLUCAGON; HUMANS; INSULIN; MEALS; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; UP-REGULATION;

EID: 84879676416     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0018     Document Type: Article

References (19)

1. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283: 109-115.
2. Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837-848.
3. Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II dia-betics. Diabetes 36: 274-283.
4. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, et al. (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects andtype 2 diabetic patients. Diabetes 57: 1340-1348.
5. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N, et al. (2003) Obesity and type 2 diabetes in Japanese patients. Lancet 361: 85.
6. Hamaguchi T, Fukushima H, Uehara M, Wada S, Shirotani T, et al. (1991) Abnormal glucagon response to arginine and its normalization in obese hyperinsuli-naemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells. Diabetologia 34: 801-806.
7. Lee S, Yabe D, Nohtomi K, Takada M, Morita R, et al. (2010) Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 57: 119-126.
8. Kawamori D, Kulkarni RN (2009) Insulin modulationof glucagon secretion: the role of insulin and other fac-tors in the regulation of glucagon secretion. Islets 1: 276-279.
9. Kozawa J, Okita K, Imagawa A, Iwahashi H, Holst JJ, et al. (2010) Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochem Biophys Res Commun 393: 410-413.
10. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 3: 39-40.
11. Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M (2005) Impact of glucagon response on postprandial hyperglycemia in men with impaired glu-cose tolerance and type 2 diabetes mellitus. Metabolism 54: 1168-1173.
12. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, et al. (1992) Role of reduced suppression of glu-cose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326: 22-29.
13. Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, et al. (2006) Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 290: E67-E77.
14. Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, et al. (2012) Impaired incretin effect and fasting hyperglu-cagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 14: 500-510.
15. Ferrannini E, Muscelli E, Natali A, Gabriel R, Mitrakou A, et al. (2007) Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia 50: 2342-2347.
16. Ohneda A, Ishii S, Horigome K, Sakai T, Kai Y, et al. (1978) Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 46: 504-510.
17. Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, et al. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553.
18. Holst JJ, Vilsbøll T, Deacon CF (2009) The incretin sys-tem and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297: 127-136.
19. De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F, et al. (2010) GLP-1 inhibits and adrena-line stimulates glucagon release by differential modula-tion of N-and L-type Ca2+ channel-dependent exocy-tosis. Cell Metab 11: 543-553.